Platform for Cloning and Modifying DNA

A DNA engineering platform employs new technology called lambda mediated cloning, or Red/ET Recombination, which allows for cloning and precise modification of DNA molecules, regardless of size and composition.

The technology allows researchers to quickly and efficiently build DNA engineering portfolios, often reducing waiting time for results from around three months to only two weeks or less. Modifications such as point mutations, sequence insertions, and deletions can be carried out at any chosen position on a target DNA molecule. The technology was originally developed at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, by the cofounders of Gene Bridges GmbH (Dresden, Germany), which is now commercializing the technology. Red/ET Recombination is available through a licensing arrangement or via a service contract, whereby researchers can send to Gene Bridges the DNA materials they would like to have modified.

"In terms of DNA cloning and subcloning, Red/ET Recombination is a far superior alternative to traditional in vitro DNA amplification strategies, which rely on inconvenient restriction sites and are prone to mutations derived from PCR amplification,” said Prof. Francis Stewart, chairman of Gene Bridges.


Related Links:
Gene Bridges